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Background: The effects of genetic variants related to the pharmacodynamic mechanisms of 
immunosuppressive drugs on their therapeutic efficacy and safety have been poorly explored. 
This study was performed to investigate the influence of the PPP3CA c.249G>A variant on the 
clinical outcomes of kidney transplant recipients.
Patients and methods: A total of 148 Brazilian patients received tacrolimus (TAC)-based 
immunosuppressive therapy for 90 days post-kidney transplantation. The PPP3CA rs3730251 
(c.249G>A) polymorphism was determined by real-time polymerase chain reaction. Single-
nucleotide polymorphism (SNP) data for CYP3A5 rs776746 (CYP3A5*3C; g.6986A>G) were 
used to eliminate the confounding effects of this variant.
Results: The PPP3CA c.249G>A SNP did not influence early TAC exposure, renal function, or 
other laboratory parameters, including levels of urea, creatinine, glucose, and lipids, and blood 
counts. This variant also did not account for the cumulative incidence of biopsy-confirmed 
acute rejection or delayed graft function. Regarding adverse events, PPP3CA c.249A allele 
carriers initially had a 3.05-fold increased probability of treatment-induced blood and lymphatic 
system disorders compared with c.249GG genotype individuals (95% confidence interval: 
1.10–8.48, p=0.032). However, this result was not maintained after adjusting for body weight 
and CYP3A5*3C SNP status (p=0.086).
Conclusion: The PPP3CA c.249G>A variant does not influence the clinical outcomes of 
Brazilian patients in the early phase of TAC-based immunosuppressive regimen.
Keywords: kidney transplantation, polymorphism, PPP3CA, tacrolimus, adverse events, 
Brazilian patients
Introduction
Pharmacogenetic approaches that focus on the pharmacodynamic mechanisms of drugs 
have the potential to increase the therapeutic efficacy and safety.1 For immunosup-
pressive drugs used in kidney transplantation, the effects of genetic variants related to 
these mechanisms on clinical outcomes have been poorly explored.
Tacrolimus (TAC) is an effective immunosuppressive agent. It can bind to FKBP12, 
and then this complex can bind to calcineurin, resulting in inhibition of the nuclear 
translocation of nuclear factor of activated T cells, and less activation of genes, includ-
ing the one encoding interleukin-2 (IL-2).2,3 Consequently, both cytokine synthesis 
and T cell activation decrease.3
Calcineurin is a Ca2+/calmodulin-dependent serine/threonine phosphatase that is com-
posed of catalytic A (CnA) and regulatory B subunits.4 For CnA, three isoforms encoded 
by PPP3CA (CnAα), PPP3CB (CnAβ), and PPP3CC (CnAγ) have been  identified.5 Both 
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the α and β isoforms are ubiquitously expressed, whereas γ is 
expressed in the testis and brain tissues.4,6
PPP3CA is located on human chromosome 4, and 
many single-nucleotide polymorphisms (SNPs) have been 
described at the PPP3CA locus.7,8 Several studies have 
explored the association of genetic variants at the PPP3CA 
locus with physiological and pathological conditions, such 
as athletic status, susceptibility to addiction, and cardiac 
hypertrophy.5,9,10 However, to the best of our knowledge, only 
two studies have evaluated the association of the PPP3CA 
SNPs with the efficacy and toxicity of calcineurin inhibitors 
in renal transplantation.11,12
This study was designed to investigate the effect of the 
PPP3CA c.249G>A SNP on the clinical outcomes of TAC-
based immunosuppression in a prospective cohort of Brazil-
ian patients in the early phase after kidney transplantation.
Patients and methods
Patients and immunosuppressive 
regimens
This investigation was performed with Brazilian adult recipi-
ents (n=148) undergoing kidney transplantation for the first 
time and who had previously enrolled in a prospective core 
study,13 registered at ClinicalTrials.gov NCT01802268. The 
study protocol was approved by the institutional review 
boards of the School of Pharmaceutical Sciences, University 
of Sao Paulo, and the Federal University of Sao Paulo/Sao 
Paulo Hospital (Sao Paulo, Brazil). All subjects provided 
written informed consent before enrollment.
Within 48 h after the transplant surgery, all patients 
received TAC (0.1–0.2 mg/kg/day), enteric-coated myco-
phenolate sodium (MPS, initial fixed dose, 1440 mg/day), 
and prednisone (initial dose, 0.5 mg/kg/day; maximum, 
30 mg with subsequent reduction to reach the maintenance 
dose of 5 mg/day by day 45). The TAC dose was adjusted to 
maintain a blood concentration in the range of 8–15 ng/mL 
in the first month and 5–15 ng/mL during the second and 
third months of therapy.
Therapy monitoring and laboratory tests
Patients were followed for 3 months posttransplantation. 
Clinical outcome assessments included monitoring the fol-
lowing variables: episodes of the biopsy-confirmed acute 
rejection (BCAR, according to the Banff 1997 classifica-
tion14) and delayed graft function (DGF, defined as the use 
of dialysis within 7 days of the transplant), renal function, 
adverse events (AEs), and other clinical laboratory tests that 
were performed on blood samples that had been collected at 
every visit under fasting conditions (levels of urea, creatinine, 
glucose, and lipids, and blood counts).
Trough TAC concentrations in blood were determined 
by chemiluminescent microparticle immunoassay using 
ARCHITECT analyzers (Abbott Diagnostics, Abbott Park, 
IL, USA). The TAC dose-adjusted trough concentrations 
in blood (C/D ratio; ng/(mL⋅mg)) were calculated. The 
estimated glomerular filtration rate (eGFR) was determined 
using the four-variable Modification of Diet in Renal Disease 
formula.15
AEs were defined as any untoward medical occurrence 
in a subject, with or without a causal relationship with drug 
treatment.16,17 All AEs were recorded and classified accord-
ing to the System Organ Class of the Medical Dictionary 
for Regulatory Activities (MedDRA).18 Duplication of AEs 
was not considered.
Genomic DNA extraction and 
genotyping by real-time PCR
Genomic DNA was extracted from pretransplant whole-blood 
samples using the QIAcube system (Qiagen, Hilden, Germany) 
and quantified using a Nanodrop ND-1000 instrument (Nano-
Drop Technologies, Wilmington, DE, USA). DNA integrity 
was evaluated using 0.8% agarose gel electrophoresis.
Subjects were genotyped for the PPP3CA rs3730251 
(c.249G>A) and CYP3A5 rs776746 (CYP3A5*3C; 
g.6986A>G) polymorphisms.
The SNP PPP3CA rs3730251 (c.249G>A) was selected 
for further investigation because it is present at the greatest 
global minor allele frequency among validated synony-
mous coding SNPs available from the Database of Single 
Nucleotide Polymorphisms (dbSNP) of the National Center 
for Biotechnology Information (NCBI).19 This variant was 
identified by real-time polymerase chain reaction (PCR), 
using a C_25618069_10 predesigned TaqMan® SNP genotyp-
ing assay (Thermo Fisher Scientific, Waltham, MA, USA). 
PCR amplification was carried out in a 7500 Fast Real-Time 
PCR thermocycler (Thermo Fisher Scientific) according to 
the manufacturer’s instructions.
The SNP CYP3A5 rs776746 (CYP3A5*3C; g.6986A>G) 
was found to be the strongest predictor of TAC dosing 
requirements.20 Genotyping results for this variant were 
presented in a previous study.21
Statistical analysis
For pharmacogenetic analyses, individuals carrying the 
homozygous form of the less common allele (PPP3CA 
c.249A) were grouped with heterozygous carriers.
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Categorical variables were described as numbers and 
percentages and compared using the c2 or Fisher’s exact test. 
Estimates of Hardy–Weinberg Equilibrium (HWE) were also 
determined using the c2 test.
Quantitative variables were expressed as mean ± standard 
deviation. For two-group comparisons, Student’s t-test (para-
metric) or Mann–Whitney test (nonparametric) was used. 
Stratification analyses based on CYP3A5*3C polymorphism 
were performed to eliminate the confounding effects of this 
variant on the results.
Logistic regression analysis was performed to assess the 
influence of the PPP3CA c.249G>A polymorphism on the risk 
of AEs, BCAR, and DGF. The following covariates were con-
sidered: recipient body weight, TAC concentration, MPS and 
prednisone doses, and CYP3A5*3C SNP genotype. Multicol-
linearity was assessed based on two closely related statistics: 
the tolerance level (>0.1) and variance inflation factor (<10). 
Goodness of fit was assessed using the Hosmer–Lemeshow 
test; for this test, p>0.05 was regarded as satisfactory.
Statistical analyses were performed using GraphPad 
Prism® (GraphPad Software, La Jolla, CA, USA) and SPSS 
for Windows (SPSS Inc., Chicago, IL, USA). Significance 
level was set at p<0.05.
Results
Patients and PPP3CA c.249G>A SNP 
genotype
The cohort of Brazilian kidney transplant recipients pre-
dominantly comprised young men (mean age, 45±13 years; 
69.6%). The frequency of hypertension, diabetes, and 
dyslipidemia was 52.0%, 12.8%, and 2.7%, respectively 
(Table 1). The cumulative incidence rates of BCAR and 
DGF were 24.3% and 19.6%, respectively. After 90 days of 
immunosuppressive therapy, the TAC blood concentration 
was 5.9±2.6 ng/mL. In the same period, the MPS and pred-
nisone doses administered were 1377.9±200.5 and 5.6±3.0 
mg/day, respectively (Table 1). The donors were mostly 
young women (mean age, 43±10 years; 53.4%). Living donor 
transplants represented the major type of transplantation 
(58.8%; Table 1).
Genotype frequencies for the PPP3CA rs3730251 
(c.249G>A) variant were as follows: GG: 87.8%, GA: 
10.8%, and AA: 1.4%. This genotype distribution was in 
HWE. The frequency of the PPP3CA c.249A allele (6.8%, 
data not shown) was in accordance to that described by the 
1000 Genomes Project (for all individuals).22
To obtain a more detailed analysis, anthropometric and 
clinical characteristics were evaluated in subgroups of the 
patients based on the presence of the PPP3CA c.249G>A SNP. 
Age, type of transplantation, and frequencies of sex, ethnicity, 
comorbidities, BCAR, and DGF were similar between PPP3CA 
c.249A allele carriers (c.249GA+AA genotypes) and c.249GG 
genotype patients (p>0.05, data not shown). However, PPP3CA 
c.249GG patients had higher mean body weight (67.1±12.5 kg) 
than c.249A allele carriers (59.7±11.4 kg, p=0.028).
Associations among PPP3CA c.249G>A 
SNP, drug exposure, and treatment 
outcomes
As expected, the PPP3CA c.249G>A SNP did not influence 
either TAC exposure (dose, concentration, or C/D) or doses 
of MPS and prednisone administered during the study period 
(data not shown). Blood concentrations of TAC are strongly 
influenced by the CYP3A5*3C SNP;20 therefore, these data 
were also analyzed and compared after stratification based 
on this variant. No significant association was identified.
Table 1 Biodemographical and clinical characteristics of Brazilian 
kidney transplant recipients and donors
Variables Patients, n=148
Recipients
Age (years) 45.4±12.9
Body weight (kg) 66.3±12.6
Sex, male 103 (69.6)
Ethnicity
White 69 (46.6)
Mixed 53 (35.8)
African 18 (12.2)
Others 8 (5.4)
Comorbidities
Hypertension 77 (52.0)
Diabetes 19 (12.8)
Dyslipidemia 4 (2.7)
Biopsy-confirmed acute rejectiona 36 (24.3)
Delayed graft functionb 29 (19.6)
Donors
Age (years) 43.4±10.3
Sex, male 68 (45.9)
Missing data 1 (0.7)
Living donor 87 (58.8)
Ethnicity
White 82 (55.4)
Mixed 46 (31.1)
African 14 (9.5)
Others 4 (2.7)
Missing data 2 (1.3)
Immunosuppression at 90 days
Tacrolimus concentration (ng/mL) 5.9±2.6
Mycophenolate sodium dose (mg/day) 1377.9±200.5
Prednisone dose (mg/day) 5.6±3.0
Notes: Values are represented as n (%). Age, body weight, and concentration and 
doses of the immunosuppressive drugs are presented as mean ± standard deviation. 
aCumulative incidence. bDefined as the use of dialysis within 7 days of the transplant.
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Similarly, the PPP3CA c.249G>A polymorphism was 
not associated with differences in eGFR or other laboratory 
parameters, including levels of urea, creatinine, glucose, and 
lipids, and blood counts (data not shown).
Logistic regression analyses were performed to determine 
whether the PPP3CA c.249G>A SNP could account for the cumu-
lative incidence of BCAR, DGF, or AEs in this study (Table 2).
With regard to AEs, the PPP3CA c.249A allele carriers 
initially had a 3.05-fold greater probability of treatment-
induced blood and lymphatic system disorders compared with 
c.249GG genotype patients (95% confidence interval: 1.10–
8.48, p=0.032; Table 2). However, this association was not 
maintained after adjusting for body weight and CYP3A5*3C 
(rs776746) SNP status (Table 2). Adjustments for patient body 
weight were necessary because previous analyses had indicated 
that PPP3CA c.249GG patients were heavier than c.249A 
allele carriers. Moreover, an adjustment for TAC concentra-
tions and doses of MPS and prednisone was performed. No 
significant result was detected (data not shown).
Discussion
Therapeutic drug monitoring (TDM) of TAC plays an impor-
tant role in patient management. The goal of TDM is to use 
drug concentrations to manage the medication regimen of 
a patient and optimize clinical outcomes.23 However, the 
amount of drug measured in the blood does not accurately 
reflect its pharmacological effects.24
Biomarkers may be useful as they can quantitatively reflect 
the effects of a given drug on its target and also predict the clini-
cal response to a drug.25 As the quantity of genetic data grows, 
genotyping will increasingly yield these useful biomarkers.26
This exploratory study was the first to investigate the 
effects of the PPP3CA c.249G>A SNP on the efficacy and 
safety of a TAC-based regimen in Brazilian kidney transplant 
recipients who were followed for the first 3 months after trans-
plantation. Moreover, it was the first investigation to evaluate 
the relationship of PPP3CA polymorphisms with different 
classes of AEs. In this study, the PPP3CA c.249G>A SNP was 
not associated with risk of DGF, BCAR, or AEs. Moreover, 
this polymorphism was not associated with eGFR, biochemi-
cal blood tests, or early drug exposure in our patient cohort.
In accord with these findings, five other SNPs (rs13146281, 
rs7665292, rs2201677, rs10031159, and rs13117493) and 
one short tandem repetition (rs45441997) in PPP3CA were 
also not associated with risk of acute or subclinical rejec-
tion, or with serious infections in renal transplant recipients 
treated with calcineurin inhibitors.11,12 Similarly, variants 
in other genes that encode components of the calcineurin 
pathway, such as FKBP1A (FKBP12), PPP3CB and PPP3R1 
(calcineurin B, α subunit), CALM1, 2, and 3 (calmodulin 
1–3 isoforms), showed no association with the outcomes of 
treatment in renal patients.11,12
We must note that these studies are in the preliminary 
stages; therefore, further investigations involving PPP3CA 
polymorphisms and responses to therapy in kidney trans-
plantation should be conducted. Indeed, until now, all of the 
studies had inherent limitations, including the sample size 
and number of genetic variants evaluated.
Noceti et al25 suggested a strong association between 
TAC pharmacodynamic parameters and polymorphisms in 
Table 2 Logistic regression analysis of association of PPP3CA 
c.249G>A polymorphism with clinical outcomes up to 90 days 
after kidney transplantation
Dependent variable Unadjusted logistic 
regression
Adjusted logistic 
regressiona
OR (95% CI) p OR (95% CI) p
Adverse events
Gastrointestinal 
disorders
0.86  
(0.30–2.45)
0.773 0.75  
(0.24–2.40)
0.630
Constipation 0.54  
(0.15–1.99)
0.357 0.34  
(0.07–1.61)
0.172
Diarrhea 0.90  
(0.30–2.69)
0.847 1.08  
(0.34–3.38)
0.899
Dyspeptic  
syndrome
0.93  
(0.25–3.48)
0.915 0.80  
(0.20–3.18)
0.754
Nausea and/or 
vomiting
0.89  
(0.19–4.24)
0.884 0.42  
(0.05–3.54)
0.428
Infections and 
infestations
1.29  
(0.46–3.66)
0.631 1.45  
(0.47–4.52)
0.518
Metabolism and 
nutrition disorders
1.00  
(0.33–3.02)
0.994 1.31  
(0.41–4.17)
0.645
Nervous system 
disorders
0.93  
(0.31–2.79)
0.899 0.96  
(0.31–3.02)
0.945
Headache 1.42  
(0.37–5.47)
0.606 1.25  
(0.31–5.10)
0.756
Renal and urinary 
disorders
1.60  
(0.58–4.44)
0.367 1.85  
(0.63–5.45)
0.267
Blood and lymphatic 
system disorders
3.05  
(1.10–8.48)
0.032 2.66  
(0.87–8.13)
0.086
Anemia 2.92  
(0.98–8.72)
0.055 2.42  
(0.70–8.29)
0.161
Musculoskeletal and 
connective tissue 
disorders
1.33  
(0.40–4.41)
0.642 1.27  
(0.36–4.48)
0.709
Skin and subcutaneous 
tissue disorders
0.32  
(0.04–2.57)
0.286 0.40  
(0.05–3.25)
0.389
Biopsy-confirmed acute 
rejection
1.67  
(0.58–4.82)
0.346 2.27  
(0.73–6.99)
0.154
Delayed graft function 1.70  
(0.55–5.22)
0.355 1.27  
(0.37–4.40)
0.706
Notes: Reference: PPP3CA c.249GG. aAdjusted for body weight and CYP3A5*3C 
(rs776746) SNP status. Bold indicates significance.
Abbreviations: OR, odds ratio; CI, confidence interval; SNP, single nucleotide 
polymorphism.
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PPP3CA. The authors reported that, in ex vivo TAC-treated 
peripheral blood mononuclear cells from 35 volunteers, the 
PPP3CA rs45441997 variant was associated with variabil-
ity in intracellular IL-2 expression in CD4+ T cells.25 IL-2, 
discovered as a T cell growth factor, is a cytokine produced 
after antigen activation that plays pivotal roles in the immune 
response.27 Its transcription can be inhibited by TAC. Stud-
ies involving IL2 polymorphisms have yielded encouraging 
results. The IL2 rs2069763 and rs2069762 variants, for 
example, have been associated with acute rejection in Turkish 
and Brazilian kidney transplant recipients.28,29
Conclusion
The results reported here indicate that the PPP3CA 
c.249G>A variant does not influence clinical outcomes in 
Brazilian patients who are in the early phase of TAC-based 
immunosuppressive regimen.
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